Foamix Pharma Names David Domzalski as CEO

June 29, 2017

Foamix Pharmaceuticals, a clinical stage specialty pharmaceutical company, appointed David Domzalski as chief executive officer, effective immediately. Domzalski currently serves as president of Foamix’s U.S. unit.
He succeeds Dr. Dov Tamarkin as CEO. Dr. Tamarkin will continue to be a member of the company’s board and will serve as chief scientific advisor to Foamix.

The company also said Meir Eini will be stepping down from his current role of chief innovation officer and will continue to serve as an innovation advisor to Foamix. Ilan Hadar, the current chief financial officer of Foamix, will assume the role of country manager in Israel, in addition to his role as chief financial officer.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.

By Stephen Holmes

Free Email Newsletter


Enter your email address below to get the latest news and analysts' ratings for your stocks with MarketBeat's FREE daily email newsletter: